S0^0!QNx0u+ L\ww\F2

:N 0~X o^:oWzvWH ~ r]rQ3]/Q }D_0|0\|_= g[ {rBP4 n;?` oCn// osqyKsqyG kf; }F%F+9F%x9 vBj@WF/@&p C@k @Pe@dI. ^AlkA`A D@ w!72 9nK,{c6 _L m6-F{- j$8n^}h1^$} @Dy)Z&DA@ (;DiH ;I If%0 Iu/: W OCfnKnB0t[ b7) ps4nMJ] bJf=g& 5S (jp(o[ OswACuwV.

S0^0!QNx0u+ L\ww\F2

:N 0~X o^:oWzvWH ~ r]rQ3]/Q }D_0|0\|_= g[ {rBP4 n;?` oCn// osqyKsqyG kf; }F%F+9F%x9 vBj@WF/@&p C@k @Pe@dI. ^AlkA`A D@ w!72 9nK,{c6 _L m6-F{- j$8n^}h1^$} @Dy)Z&DA@ (;DiH ;I If%0 Iu/: W OCfnKnB0t[ b7) ps4nMJ] bJf=g& 5S (jp(o[ OswACuwV.

9ZA{C! ^[Lq
Yss atZ7i
Jtt]Rtt
Jtt]Rtt
`K
`K
+R+ 0t
+R+ 0t
Y0Y 4m[
Y0Y 4m[
pL 07G
pL 07G
V2V GrK
V2V GrK
x`x D]}`] 2X#% e%@k`
x`x D]}`] 2X#% e%@k`
n\ZAh/S@|l *t!{*!& f)A[~~ ?N2e!/N/=e[0
n\ZAh/S@|l *t!{*!& f)A[~~ ?N2e!/N/=e[0
Qg PVVᵃ
Qg PVVᵃ
GvG 8T
GvG 8T
3^3 _ZZ
3^3 _ZZ
;9 pOO3DOO†
;9 pOO3DOO†
W)W :: {EJ= X)dd%d\K
W)W :: {EJ= X)dd%d\K
##hK#D@
##hK#D@
:Ukg?? l_u8UJ_J}8&C
:Ukg?? l_u8UJ_J}8&C
E;::II {s!~O/s/K~O2†
E;::II {s!~O/s/K~O2†
Y`Y C;L 07G {s{ Jzz
Y`Y C;L 07G {s{ Jzz
I@I ;)A
I@I ;)A
pQp `8,g8
pQp `8,g8
r2ZSr2I Z]Z:lUw&[M V[T-g#TqO-K
r2ZSr2I Z]Z:lUw&[M V[T-g#TqO-K
I#q#f (d4wws7s(
I#q#f (d4wws7s(
[NNyEyUymF |_!`Y _|ssiiiip_r|
[NNyEyUymF |_!`Y _|ssiiiip_r|
G$V}[bu}6 ;/; z38f))
G$V}[bu}6 ;/; z38f))
D) i7A6$ C`2\2
D) i7A6$ C`2\2
`} ^; U$E5E
`} ^; U$E5E
[M;1 xvLyL
[M;1 xvLyL
{lR~eud $AY&Y
{lR~eud $AY&Y
|@ NlMlvUv
|@ NlMlvUv
?q V;yy
?q V;yy
(~ $^//
(~ $^//
52 =a##
52 =a##
:# {]^{6m]
:# {]^{6m]
^s 0}l
^s 0}l
p( Uii
p( Uii
-v 2hi
-v 2hi
45/O Pjj
45/O Pjj
V3 p6]t] bn?Ww?q~N@O?n 8MqpEYL,qM-i
V3 p6]t] bn?Ww?q~N@O?n 8MqpEYL,qM-i
7= [2jD$ 2a42 q0UeU
7= [2jD$ 2a42 q0UeU
d[SJS (G,R au`*a$t&`au`
d[SJS (G,R au`*a$t&`au`
3N ;rb k9?ry /w`J/T
3N ;rb k9?ry /w`J/T
3[ELR =:L2=x
3[ELR =:L2=x
yjj}DiD
yjj}DiD
+y EUv]v
+y EUv]v
b_g T5iui
b_g T5iui
wZ efCvv
wZ efCvv
sp ~;j5p };x
sp ~;j5p };x
j4 KhRbQ 0g&
j4 KhRbQ 0g&
{XTuK!/uV ^8
{XTuK!/uV ^8
M@ ))} ^&ScaS 7sJS
M@ ))} ^&ScaS 7sJS
y_ Q737
y_ Q737
l[)[olo
l[)[olo
tV 0jpj
tV 0jpj
*8=W8
*8=W8
)A!I@
1oo 8BB\)\
I
I
C
C
o
o
9ZA{C! ^[Lq
Yss atZ7i
Jtt]Rtt
Jtt]Rtt
`K
`K
+R+ 0t
+R+ 0t
Y0Y 4m[
Y0Y 4m[
pL 07G
pL 07G
V2V GrK
V2V GrK
x`x D]}`] 2X#% e%@k`
x`x D]}`] 2X#% e%@k`
n\ZAh/S@|l *t!{*!& f)A[~~ ?N2e!/N/=e[0
n\ZAh/S@|l *t!{*!& f)A[~~ ?N2e!/N/=e[0
Qg PVVᵃ
Qg PVVᵃ
GvG 8T
GvG 8T
3^3 _ZZ
3^3 _ZZ
;9 pOO3DOO†
;9 pOO3DOO†
W)W :: {EJ= X)dd%d\K
W)W :: {EJ= X)dd%d\K
##hK#D@
##hK#D@
:Ukg?? l_u8UJ_J}8&C
:Ukg?? l_u8UJ_J}8&C
E;::II {s!~O/s/K~O2†
E;::II {s!~O/s/K~O2†
Y`Y C;L 07G {s{ Jzz
Y`Y C;L 07G {s{ Jzz
I@I ;)A
I@I ;)A
pQp `8,g8
pQp `8,g8
r2ZSr2I Z]Z:lUw&[M V[T-g#TqO-K
r2ZSr2I Z]Z:lUw&[M V[T-g#TqO-K
I#q#f (d4wws7s(
I#q#f (d4wws7s(
[NNyEyUymF |_!`Y _|ssiiiip_r|
[NNyEyUymF |_!`Y _|ssiiiip_r|
G$V}[bu}6 ;/; z38f))
G$V}[bu}6 ;/; z38f))
D) i7A6$ C`2\2
D) i7A6$ C`2\2
`} ^; U$E5E
`} ^; U$E5E
[M;1 xvLyL
[M;1 xvLyL
{lR~eud $AY&Y
{lR~eud $AY&Y
|@ NlMlvUv
|@ NlMlvUv
?q V;yy
?q V;yy
(~ $^//
(~ $^//
52 =a##
52 =a##
:# {]^{6m]
:# {]^{6m]
^s 0}l
^s 0}l
p( Uii
p( Uii
-v 2hi
-v 2hi
45/O Pjj
45/O Pjj
V3 p6]t] bn?Ww?q~N@O?n 8MqpEYL,qM-i
V3 p6]t] bn?Ww?q~N@O?n 8MqpEYL,qM-i
7= [2jD$ 2a42 q0UeU
7= [2jD$ 2a42 q0UeU
d[SJS (G,R au`*a$t&`au`
d[SJS (G,R au`*a$t&`au`
3N ;rb k9?ry /w`J/T
3N ;rb k9?ry /w`J/T
3[ELR =:L2=x
3[ELR =:L2=x
yjj}DiD
yjj}DiD
+y EUv]v
+y EUv]v
b_g T5iui
b_g T5iui
wZ efCvv
wZ efCvv
sp ~;j5p };x
sp ~;j5p };x
j4 KhRbQ 0g&
j4 KhRbQ 0g&
{XTuK!/uV ^8
{XTuK!/uV ^8
M@ ))} ^&ScaS 7sJS
M@ ))} ^&ScaS 7sJS
y_ Q737
y_ Q737
l[)[olo
l[)[olo
tV 0jpj
tV 0jpj
*8=W8
*8=W8
)A!I@
1oo 8BB\)\
I
I
C
C
o
o
qb(lb]tC
PUPPmPP =SO9 %r coMoeI0U
)A!I@
z|!HK^H)}!}K 3 KrB Q}!Q)Qvu^
Jtt]Rtt
I
y_OgR_Kgl_E
Jtt]Rtt
`K
I
y_OgR_Kgl_E
`K
+R+ 0t
I
y_OgR_Kgl_E
+R+ 0t
Y0Y 4m[
I
y_OgR_Kgl_E
Y0Y 4m[
pL 07G
I
y_OgR_Kgl_E
pL 07G
V2V GrK
C
y_OgR_Kgl_E
V2V GrK
x`x D]}`] 2X#% e%@k`
C
y_OgR_Kgl_E
x`x D]}`] 2X#% e%@k`
n\ZAh/S@|l *t!{*!& f)A[~~ ?N2e!/N/=e[0
C
y_OgR_Kgl_E
n\ZAh/S@|l *t!{*!& f)A[~~ ?N2e!/N/=e[0
`Y~YYlYI5U: , @?K: Me(M@MYcA
Qg PVVᵃ
I
y_OgR_Kgl_E
Qg PVVᵃ
GvG 8T
C
y_OgR_Kgl_E
GvG 8T
3^3 _ZZ
C
y_OgR_Kgl_E
3^3 _ZZ
V2V GrK
C
y_OgR_Kgl_E
V2V GrK
;9 pOO3DOO†
C
y_OgR_Kgl_E
;9 pOO3DOO†
W)W :: {EJ= X)dd%d\K
o
y_OgR_Kgl_E
W)W :: {EJ= X)dd%d\K
##hK#D@
o
y_OgR_Kgl_E
##hK#D@
:Ukg?? l_u8UJ_J}8&C
o
y_OgR_Kgl_E
:Ukg?? l_u8UJ_J}8&C
QDQtJ++K] P deR ZoPZ
:Ukg?? l_u8UJ_J}8&C
o
y_OgR_Kgl_E
:Ukg?? l_u8UJ_J}8&C
E;::II {s!~O/s/K~O2†
o
y_OgR_Kgl_E
E;::II {s!~O/s/K~O2†
Y`Y C;L 07G {s{ Jzz
C
y_OgR_Kgl_E
Y`Y C;L 07G {s{ Jzz
z,z%roDDl B iUQ8 ~1| q3s$ C8YC]CBcF
:Ukg?? l_u8UJ_J}8&C
o
y_OgR_Kgl_E
:Ukg?? l_u8UJ_J}8&C
|YFz]zYWr+Yi ` VcXw 5!x
I@I ;)A
I
y_OgR_Kgl_E
I@I ;)A
}&uNR=nu[og = fxLxf /8;
pQp `8,g8
o
y_OgR_Kgl_E
pQp `8,g8
z|!HK^H)}!}K 3 KrB Q}!Q)Qvu^
r2ZSr2I Z]Z:lUw&[M V[T-g#TqO-K
I
y_OgR_Kgl_E
r2ZSr2I Z]Z:lUw&[M V[T-g#TqO-K
I#q#f (d4wws7s(
C
y_OgR_Kgl_E
I#q#f (d4wws7s(
a4a9r?Yn? Q P(,rL hJ0h
[NNyEyUymF |_!`Y _|ssiiiip_r|
o
y_OgR_Kgl_E
[NNyEyUymF |_!`Y _|ssiiiip_r|
eE!g!(Xr9r!L¹ y ;fc C x1x! 6KCx
G$V}[bu}6 ;/; z38f))
C
y_OgR_Kgl_E
G$V}[bu}6 ;/; z38f))
|YFz]zYWr+Yi ` VcXw 5!x
D) i7A6$ C`2\2
I
y_OgR_Kgl_E
D) i7A6$ C`2\2
`} ^; U$E5E
I
y_OgR_Kgl_E
`} ^; U$E5E
[M;1 xvLyL
I
y_OgR_Kgl_E
[M;1 xvLyL
{lR~eud $AY&Y
I
y_OgR_Kgl_E
{lR~eud $AY&Y
|@ NlMlvUv
I
y_OgR_Kgl_E
|@ NlMlvUv
?q V;yy
I
y_OgR_Kgl_E
?q V;yy
(~ $^//
I
y_OgR_Kgl_E
(~ $^//
52 =a##
I
y_OgR_Kgl_E
52 =a##
:# {]^{6m]
I
y_OgR_Kgl_E
:# {]^{6m]
^s 0}l
I
y_OgR_Kgl_E
^s 0}l
p( Uii
I
y_OgR_Kgl_E
p( Uii
-v 2hi
I
y_OgR_Kgl_E
-v 2hi
45/O Pjj
C
y_OgR_Kgl_E
45/O Pjj
V3 p6]t] bn?Ww?q~N@O?n 8MqpEYL,qM-i
o
y_OgR_Kgl_E
V3 p6]t] bn?Ww?q~N@O?n 8MqpEYL,qM-i
}&uNR=nu[og = fxLxf /8;
7= [2jD$ 2a42 q0UeU
I
y_OgR_Kgl_E
7= [2jD$ 2a42 q0UeU
d[SJS (G,R au`*a$t&`au`
o
y_OgR_Kgl_E
d[SJS (G,R au`*a$t&`au`
ll^u__&J² D ?g{r o+Wo[oZ/i
3N ;rb k9?ry /w`J/T
o
y_OgR_Kgl_E
3N ;rb k9?ry /w`J/T
8a8FPAAH6 g P@Q- HnCH=Hm&&
3N ;rb k9?ry /w`J/T
o
y_OgR_Kgl_E
3N ;rb k9?ry /w`J/T
Y^9KyO\@³ S ZL:= ofg
3N ;rb k9?ry /w`J/T
o
y_OgR_Kgl_E
3N ;rb k9?ry /w`J/T
:\:6C-NL r Tw{` y)L
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
)i)0WWv⁴ q 3ndG 2^F
yjj}DiD
C
y_OgR_Kgl_E
yjj}DiD
?q V;yy
C
y_OgR_Kgl_E
?q V;yy
z}TZGccGᵇ R _C Wj%MofPnojfA
+y EUv]v
C
y_OgR_Kgl_E
+y EUv]v
{lR~eud $AY&Y
C
y_OgR_Kgl_E
{lR~eud $AY&Y
b_g T5iui
C
y_OgR_Kgl_E
b_g T5iui
wZ efCvv
C
y_OgR_Kgl_E
wZ efCvv
vROIeRKR\Rd⁵ C 0$~~ O|;H
sp ~;j5p };x
C
y_OgR_Kgl_E
sp ~;j5p };x
j4 KhRbQ 0g&
I
y_OgR_Kgl_E
j4 KhRbQ 0g&
d9d)cWW\ 1 DrZO v0c
{XTuK!/uV ^8
C
y_OgR_Kgl_E
{XTuK!/uV ^8
GGGzcSI9S d oNN2 phPp4p8A2
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
sLsY}X=z= M /?EJ !Lv!/!zjN
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
:k:yHv~dv y 4VHm 4,4}9,E
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
^/^98#=z8 B m(jζ -ZP-a-QGn
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
H9HAHje\\ R 77MI &|}
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
K!A~!!V~^ o Uz:U =n] #]C#4#vs&
M@ ))} ^&ScaS 7sJS
I
y_OgR_Kgl_E
M@ ))} ^&ScaS 7sJS
fi{ligigi/⁶ $ nGG1 ^ !BP P/CJ
y_ Q737
I
y_OgR_Kgl_E
y_ Q737
|@ NlMlvUv
I
y_OgR_Kgl_E
|@ NlMlvUv
l[)[olo
I
y_OgR_Kgl_E
l[)[olo
tV 0jpj
C
y_OgR_Kgl_E
tV 0jpj
NUy`DD$UmDQ⁷ G vhp]jM ^ yqG 7O%J
*8=W8
o
y_OgR_Kgl_E
*8=W8
HlH0E^]v + 4F;vf d]@=]R%
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
8S8]89dd^ , J3Oi s LBbps ;`r_
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
XZXhX-ZXX - ;o~T w WB^EE U4-j
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
TEW|JTf† $ LlGN d _\e !u]D
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
&M_2QWA† g tYt}1G +\r
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
?J?Tv,4,v† * xP,X}c, %:o%D%~]y
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
){)-s-P0`† n uljfa _hk_t_|Of
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x
oE:~jss T lg- -pv
3[ELR =:L2=x
o
y_OgR_Kgl_E
3[ELR =:L2=x

\h Qp kK1_@!_z 3G3{

oAmgen collaboration; BeiGene has China commercial rights. CEnsem collaboration; BeiGene has global rights. IDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. ILeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. hZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. )Amgen collaboration; BeiGene has development and commercialization rights in China. HAmgen collaboration; BeiGene has development and commercialization rights in China. =In combination with Zanubrutinib. {May include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. † Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Please login or register for full access

Register

Already registered?  Login